preproenkephalin and Depressive-Disorder--Major

preproenkephalin has been researched along with Depressive-Disorder--Major* in 3 studies

Other Studies

3 other study(ies) available for preproenkephalin and Depressive-Disorder--Major

ArticleYear
Impaired periamygdaloid-cortex prodynorphin is characteristic of opiate addiction and depression.
    The Journal of clinical investigation, 2013, Volume: 123, Issue:12

    Negative affect is critical for conferring vulnerability to opiate addiction as reflected by the high comorbidity of opiate abuse with major depressive disorder (MDD). Rodent models implicate amygdala prodynorphin (Pdyn) as a mediator of negative affect; however, evidence of PDYN involvement in human negative affect is limited. Here, we found reduced PDYN mRNA expression in the postmortem human amygdala nucleus of the periamygdaloid cortex (PAC) in both heroin abusers and MDD subjects. Similar to humans, rats that chronically self-administered heroin had reduced Pdyn mRNA expression in the PAC at a time point associated with a negative affective state. Using the in vivo functional imaging technology DREAMM (DREADD-assisted metabolic mapping, where DREADD indicates designer receptors exclusively activated by designer drugs), we found that selective inhibition of Pdyn-expressing neurons in the rat PAC increased metabolic activity in the extended amygdala, which is a key substrate of the extrahypothalamic brain stress system. In parallel, PAC-specific Pdyn inhibition provoked negative affect-related physiological and behavioral changes. Altogether, our translational study supports a functional role for impaired Pdyn in the PAC in opiate abuse through activation of the stress and negative affect neurocircuitry implicated in addiction vulnerability.

    Topics: Adult; Amygdala; Animals; Clozapine; Corticosterone; Depressive Disorder, Major; Designer Drugs; Enkephalins; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; GTP-Binding Protein alpha Subunits, Gi-Go; Heroin Dependence; Humans; Hungary; Limbic System; Male; Middle Aged; Neuroimaging; Neurons; Positron-Emission Tomography; Protein Precursors; Radiopharmaceuticals; Rats; Rats, Long-Evans; Recombinant Fusion Proteins; RNA, Messenger; United States

2013
Subjects with major depression or bipolar disorder show reduction of prodynorphin mRNA expression in discrete nuclei of the amygdaloid complex.
    Molecular psychiatry, 2002, Volume: 7, Issue:1

    The dynorphin system has been associated with the regulation of mood. The expression of the prodynorphin mRNA was currently studied in the amygdaloid complex, a brain region critical for emotional processing, in subjects (14-15 per group) diagnosed with major depression, bipolar disorder, or schizophrenia and compared to normal controls. In situ hybridization histochemistry was used to characterize the anatomical distribution and expression levels of the prodynorphin mRNA within the amygdaloid complex. High prodynorphin mRNA levels were expressed in the parvicellular division of the accessory basal, posterior cortical, periamygdaloid cortex, and amygdalohippocampal area in normal subjects. Individuals with major depression had significantly reduced (41-68%) expression of the prodynorphin mRNA in the accessory basal (both parvicellular and magnocellular divisions; P < 0.01) and amygdalohippocampal area (P < 0.001) as compared to controls. The bipolar disorder group also showed a significant reduction (37-38%, P < 0.01) of the mRNA expression levels in the amygdalohippocampal area and in the parvicellular division of the accessory basal. No other amygdala nuclei studied showed any significant differences for the prodynorphin mRNA levels measured in the major depression and bipolar disorder subjects. Additionally, the prodynorphin mRNA expression levels did not differ significantly between the schizophrenic and normal control subjects in any of the amygdala areas examined. These findings indicate specific prodynorphin amygdala impairment in association with mood disorder.

    Topics: Adult; Affect; Aged; Amygdala; Bipolar Disorder; Depressive Disorder, Major; Enkephalins; Female; Gene Expression Profiling; Hippocampus; Humans; In Situ Hybridization; Male; Middle Aged; Nerve Tissue Proteins; Protein Precursors; RNA, Messenger; Schizophrenia

2002
Prodynorphin and kappa opioid receptor mRNA expression in the cingulate and prefrontal cortices of subjects diagnosed with schizophrenia or affective disorders.
    Brain research bulletin, 2001, Jul-15, Volume: 55, Issue:5

    The present study examined the prodynorphin and kappa opioid receptor mRNA expression levels in the anterior cingulate and dorsolateral prefrontal cortices of subjects diagnosed with schizophrenia, bipolar disorder, or major depression as compared with normal controls without a psychiatric diagnosis. Multivariate analyses failed to reveal any differences in the mRNA expression levels between the four diagnostic groups, though a group trend (non-significant) was evident for the expression of the kappa opioid receptor and prodynorphin mRNAs in the prefrontal cortex. The mRNA expression levels were not associated with lifetime history of antipsychotic treatment or with suicide as a cause of death. The results, however, suggested an influence of certain drugs of abuse on the prodynorphin cortical mRNA expression. Prodynorphin mRNA expression levels were found to be elevated in individuals with a history of marihuana or stimulant use, but not alcohol. Overall, our data do not provide strong evidence for impaired prodynorphin or kappa opioid receptor mRNA levels in the dorsolateral prefrontal or cingulate cortices of schizophrenic, bipolar disorder, or major depressed subjects.

    Topics: Adult; Age Factors; Amphetamine-Related Disorders; Bipolar Disorder; Depressive Disorder, Major; Enkephalins; Female; Functional Laterality; Humans; In Situ Hybridization; Male; Marijuana Abuse; Middle Aged; Protein Precursors; Receptors, Opioid, kappa; RNA, Messenger; Schizophrenia; Sex Factors; Suicide

2001